<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089401</url>
  </required_header>
  <id_info>
    <org_study_id>040229</org_study_id>
    <secondary_id>04-C-0229</secondary_id>
    <secondary_id>CDR0000378323</secondary_id>
    <nct_id>NCT00089401</nct_id>
    <nct_alias>NCT00086697</nct_alias>
  </id_info>
  <brief_title>Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver</brief_title>
  <official_title>A Phase II Trial Of Isolated Hepatic Perfusion (IHP) With Melphalan For Subjects With Metastatic Unresectable Colorectal Cancers Of The Liver With Disease Refractory To First Line Systemic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different&#xD;
      ways may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well isolated hepatic perfusion with melphalan&#xD;
      works in treating patients with unresectable colorectal cancer that has metastasized to the&#xD;
      liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response and duration of response in patients with unresectable colorectal&#xD;
           cancer metastatic to the liver and refractory to first-line systemic chemotherapy&#xD;
           treated with isolated hepatic perfusion with melphalan.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pattern of recurrence (liver vs systemic) in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine hepatic progression-free and overall survival in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the time to hepatic and systemic progression in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine quality of life (QOL) in patients treated with this regimen.&#xD;
&#xD;
        -  Correlate baseline QOL with length of survival in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients undergo a limited laparotomy to determine if extrahepatic disease that was&#xD;
      not visualized during preoperative scanning is present. Patients found to have peritoneal&#xD;
      seeding or unresectable extrahepatic metastatic disease not previously visualized on scans do&#xD;
      not receive isolated hepatic perfusion (IHP). Remaining patients undergo IHP with melphalan&#xD;
      and hyperthermia therapy. Liver perfusion continues for 1 hour.&#xD;
&#xD;
      Quality of life is assessed at baseline, 6 weeks, and then every 3-4 months for 3 years.&#xD;
&#xD;
      Patients are followed at 6 weeks, every 3-4 months for 3 years, and then every 6 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns of tumor recurrence (liver vs systemic)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isolated perfusion</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed colorectal cancer&#xD;
&#xD;
               -  Metastatic disease limited to the parenchyma of the liver&#xD;
&#xD;
                    -  Patients with limited sites of extrahepatic disease AND who have dominant&#xD;
                       life-limiting disease in the liver are considered eligible provided the&#xD;
                       extrahepatic sites can be treated with local ablative measures (e.g.,&#xD;
                       resection or external beam radiotherapy)&#xD;
&#xD;
                    -  No other evidence of unresectable extrahepatic disease by radiological&#xD;
                       studies&#xD;
&#xD;
          -  Unresectable hepatic disease defined by &gt; 3 sites of disease in the liver, bilobar&#xD;
             disease, or tumor abutting major vascular or ductal structures making anatomic&#xD;
             resection with liver function preservation impossible&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Refractory to prior first-line systemic chemotherapy&#xD;
&#xD;
               -  Disease progression during or after completion of treatment with an irinotecan-&#xD;
                  or oxaliplatin-containing regimen for established hepatic metastases&#xD;
&#xD;
                    -  Treatment failure is defined as disease progression evidenced by tumor&#xD;
                       growth OR new lesions on imaging modalities OR increasing carcinoembryonic&#xD;
                       antigen (CEA)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hematocrit &gt; 27.0%&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  PT ≤ 2 seconds of the upper limit of normal&#xD;
&#xD;
          -  ALT and AST elevations secondary to metastatic disease allowed&#xD;
&#xD;
          -  Chronic active hepatitis B or C allowed provided there is no evidence of cirrhosis on&#xD;
             pathology, radiologic studies, or physical exam&#xD;
&#xD;
          -  No history of veno-occlusive disease&#xD;
&#xD;
          -  No biopsy proven cirrhosis&#xD;
&#xD;
          -  No evidence of significant portal hypertension manifested by ascites, esophageal&#xD;
             varices on endoscopy, or radiologic studies showing significant collateral vessels&#xD;
             around the organs drained by the portal venous system&#xD;
&#xD;
          -  No other liver condition that would preclude study therapy&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 40%&#xD;
&#xD;
          -  No ischemic cardiac disease&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease or other chronic pulmonary disease allowed&#xD;
             provided pulmonary function test ≥ 50% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  Weight &gt; 30 kg&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy for the malignancy and recovered&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy for the malignancy and recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy for the malignancy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs&#xD;
&#xD;
          -  No concurrent chronic anticoagulation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven K. Libutti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>May 11, 2012</last_update_submitted>
  <last_update_submitted_qc>May 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2012</last_update_posted>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

